Changeflow GovPing Healthcare & Life Sciences Patent Application: Cancer Treatment with Stat3...
Routine Notice Added Final

Patent Application: Cancer Treatment with Stat3 Decoy

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a patent application filed with the USPTO, specifically application US20260085318A1. It describes methods for treating cancer by employing a STAT3 double-stranded, cyclic oligonucleotide decoy in conjunction with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future developments in cancer therapeutics and may be of interest to pharmaceutical companies, drug manufacturers, and healthcare providers involved in oncology research and treatment. The publication date is March 26, 2026.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Methods for Treating Cancer Using a Stat3 Double-Stranded, Cyclic Oligonucleotide Decoy

Application US20260085318A1 Kind: A1 Mar 26, 2026

Inventors

Daniel E. Johnson, Jennifer R. Grandis

Abstract

The present invention provides methods of treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor.

CPC Classifications

C12N 15/1136 A61K 31/713 A61P 35/00 C07K 16/2818 C07K 16/2827 A61K 2039/505 C07K 2317/76 C12N 2310/11

Filing Date

2023-09-20

Application No.

19112832

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 20th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085318A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Drug Development Cancer Treatment
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Medical Devices Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!